{
  "id": 20759983,
  "title": "Evogene Q3 2026 slides highlight AI drug progress amid 75% revenue drop",
  "url": "https://urgent.news/2026/11/19/evogene-q3-2026-slides-highlight-ai-drug-progress-amid-75-revenue-drop",
  "topic": "ai",
  "section": "AI",
  "published": "2026-11-19T14:50:43.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/evogene-q3-2026-slides-highlight-ai-drug-progress-amid-75-revenue-drop-93CH-5039349"
  },
  "original_language": "en",
  "account": null,
  "summary": "Evogene Ltd. reported a 75% decline in Q3 2026 revenue, sliding to $822,000 from $3.2 million a year earlier, alongside a widening loss of $10.5 million, up from $2.5 million in the same period last year. Despite these financial challenges, the company highlighted significant progress in its AI-driven drug discovery and agricultural chemical programs. The ChemPass AI platform showcased promising results in developing novel small molecules for treating acute graft-versus-host disease and fungicide candidates for wheat disease. However, the company's financial position remains precarious, with total assets dropping to $12.6 million and an expanded accumulated deficit of $293.0 million.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}